Maxim Shishin Sells 2,250 Shares of CorVel (NASDAQ:CRVL) Stock

Posted by Stanley Muller on Jun 15th, 2026

CorVel Corp. (NASDAQ:CRVL – Get Free Report) insider Maxim Shishin sold 2,250 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $60.59, for a total value of $136,327.50. Following the transaction, the insider owned 7,050 shares in the company, valued at $427,159.50. This trade represents a 24.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CorVel Price Performance

Shares of NASDAQ CRVL traded down $1.45 during mid-day trading on Monday, hitting $58.89. The company had a trading volume of 197,886 shares, compared to its average volume of 222,599. The company has a market capitalization of $2.99 billion, a PE ratio of 27.52 and a beta of 0.99. CorVel Corp. has a 1-year low of $44.83 and a 1-year high of $105.69. The business’s 50-day simple moving average is $58.08 and its 200 day simple moving average is $60.06.

CorVel (NASDAQ:CRVL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 earnings per share (EPS) for the quarter. The business had revenue of $248.55 million for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen upgraded CorVel from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Weiss Ratings lowered CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

View Our Latest Stock Report on CRVL

Institutional Investors Weigh In On CorVel

Several institutional investors have recently modified their holdings of CRVL. Royal Bank of Canada raised its position in shares of CorVel by 12.5% during the 1st quarter. Royal Bank of Canada now owns 51,261 shares of the business services provider’s stock worth $5,739,000 after purchasing an additional 5,703 shares during the last quarter. AQR Capital Management LLC raised its holdings in CorVel by 4.0% in the 1st quarter. AQR Capital Management LLC now owns 26,468 shares of the business services provider’s stock valued at $2,964,000 after acquiring an additional 1,013 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in CorVel by 11.4% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,800 shares of the business services provider’s stock valued at $425,000 after acquiring an additional 389 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in CorVel by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,846 shares of the business services provider’s stock valued at $1,774,000 after acquiring an additional 702 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in CorVel by 127.4% in the 1st quarter. Millennium Management LLC now owns 48,182 shares of the business services provider’s stock valued at $5,395,000 after acquiring an additional 26,990 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About CorVel

(Get Free Report)

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).